NDA 021171 · Hospira
Demerol
Meperidine Hydrochloride · Injection
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1942
Nov 10, 1942
Approved uses
1
Original approval plus efficacy supplements
Registered trials
105
11 Phase 3, 5 recruiting
FAERS reports
9,363
5,919 serious, 764 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF DEMEROL Addiction, Abuse, and Misuse Because the use of DEMEROL Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of DEMEROL Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of DEMEROL Injection are essential [see Warnings and Precautions (5.2) ] . Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with...
What it is approved for
From the label in effect Jul 20, 2026.
DEMEROL Injection is indicated for preoperative medication, support of anesthesia, and obstetrical analgesia. DEMEROL Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DEMEROL Injection is indicated for preoperative medication, support of anesthesia, for obstetrical analgesia, and for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including DEMEROL Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Use of DEMEROL Injection for an extended period of time may increase the risk of toxicity (e.g., seizures) from the accumulation of the meperidine metabolite, normeperidine. ( 1 , 5.1 ) Limitations of Use: Because of the risks of addiction, abuse, misuse , overdose, and death , which can occur at any dosage or duration and persist over the course of therapy, [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including DEMEROL Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Use of DEMEROL Injection for an extended period of time may increase the risk of toxicity (e.g., seizures) from the accumulation of the meperidine metabolite, normeperidine.
Mechanism: Meperidine hydrochloride is an opioid agonist with multiple actions qualitatively similar to those of morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 10, 1942 Original approval
4 products under this application
- DEMEROL · MEPERIDINE HYDROCHLORIDE 75MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- DEMEROL · MEPERIDINE HYDROCHLORIDE 25MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- DEMEROL · MEPERIDINE HYDROCHLORIDE 100MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- DEMEROL · MEPERIDINE HYDROCHLORIDE 50MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Meperidine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
Ankara UniversityAcademic, hospital or other
NCT02393144 · 1,000 participants (planned) · Start Feb 2015 · Primary completion Jan 2017
Drug: Analgesics, Opioid, Meperidine; Labor augmentation, Oxytocin and 2 more · For: Pregnancy; Obstetric Labor
Sites: Ankara, Turkey (Türkiye)
- CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery)Pivotal-lookingActive, not recruiting
KK Women's and Children's HospitalGovernment (non-federal)
NCT03167905 · 881 participants · Start Jun 15, 2017 · Primary completion Jul 19, 2021
Drug: Entonox; Meperidine and 3 more · For: Depression, Postpartum; Analgesia, Obstetrical; Anesthesia, Obstetrical
Sites: Singapore, Singapore
- Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/PethidinePivotal-lookingNot yet recruiting
Fondazione Andrea Cesalpino Arezzo ONLUSAcademic, hospital or other
NCT06736938 · 530 participants (planned) · Start Apr 1, 2025 · Primary completion Apr 1, 2027
Drug: Propofol 1%; Midazolam and 1 more · For: Sedation During Bronchoscopy
Sites: Arezzo, Italy
- Effects of Bupivacaine Induced Motor Blockade During the Second Stage of LaborPivotal-lookingCompleted
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT01621230 · 481 participants · Start Sep 2009 · Primary completion Jul 2012
Drug: Epidural Bupivacaine plus fentanyl; Epidural fentanyl · For: Pregnancy
Sites: Dallas, Texas
- A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in LabourPivotal-lookingCompleted
University of BirminghamAcademic, hospital or other
NCT02179294 · 401 participants · Start May 2014 · Primary completion Sep 2016
Drug: Pethidine; Remifentanil · For: Pain Relief in Labour
Sites: Birmingham, United Kingdom
Mansoura UniversityAcademic, hospital or other
NCT05696886 · 400 participants · Start Jan 1, 2021 · Primary completion Dec 31, 2022
Drug: Pethidine; Tramadol with pethidine · For: Postoperative Pain
Sites: Al Mansurah, Egypt
- Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean SectionsPivotal-lookingCompleted
Ain Shams UniversityAcademic, hospital or other
NCT06513806 · 330 participants · Start Aug 1, 2024 · Primary completion Sep 25, 2024
Drug: Granisetron 1 Mg/mL Intravenous Solution; Pethidin · For: Anesthesia; Adverse Effect, Spinal and Epidural
Sites: Cairo, Egypt
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity3,327
- drug ineffective1,396
- pain1,290
- nausea1,278
- off label use1,014
- hyperhidrosis987
- drug intolerance829
- rash813
- overdose760
- vomiting756
- hypertension740
- headache703
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 213 |
| 2005 | 180 |
| 2006 | 178 |
| 2007 | 131 |
| 2008 | 114 |
| 2009 | 166 |
| 2010 | 198 |
| 2011 | 233 |
| 2012 | 340 |
| 2013 | 270 |
| 2014 | 375 |
| 2015 | 401 |
| 2016 | 554 |
| 2017 | 500 |
| 2018 | 664 |
| 2019 | 1,002 |
| 2020 | 722 |
| 2021 | 663 |
| 2022 | 466 |
| 2023 | 734 |
| 2024 | 519 |
| 2025 | 360 |
| 2026 | 379 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 9, 2026
Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30).
Current · updated Nov 9, 2026
Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30).
Current · updated Nov 9, 2026
Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Demerol (Meperidine HCl/PF)
2024 spending
$33K
Beneficiaries
28
88 claims
Per beneficiary
$1,161
$7.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $44,706 |
| 2021 | $44,246 |
| 2022 | $58,477 |
| 2023 | $71,081 |
| 2024 | $32,504 |
Part B: Demerol* (Meperidine HCL*) · HCPCS J2175
2024 spending
$36K
Beneficiaries
3,230
5,262 claims
Per beneficiary
$11
2024 ASP limit $6.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $80,184 |
| 2021 | $70,153 |
| 2022 | $55,045 |
| 2023 | $55,224 |
| 2024 | $35,508 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of intrathecal adjuvants for perioperative management of cesarean delivery: a systematic review and network meta-analysis of randomized controlled trials.
Ollosu M, Tripodi VF, Bonu A, et al. · Reg Anesth Pain Med 2026 · Systematic Review, Meta-Analysis
- Flumazenil in children after esophagogastroduodenoscopy.
Peters JM, Tolia V, Simpson P, et al. · Am J Gastroenterol 1999 · Clinical Trial, Randomized Controlled Trial
- Sedative techniques for endoscopic retrograde cholangiopancreatography.
Garewal D, Powell S, Milan SJ, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Epileptogenic drugs: a systematic review.
Ruffmann C, Bogliun G, Beghi E · Expert Rev Neurother 2006 · Meta-Analysis, Systematic Review
- Effect of Ondansetron on Postoperative Shivering After Craniotomy.
Teymourian H, Mohajerani SA, Bagheri P, et al. · World Neurosurg 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Transdermal fentanyl for the management of acute pancreatitis pain.
Stevens M, Esler R, Asher G · Appl Nurs Res 2002 · Clinical Trial, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.